What the research found
Peptides are short chains of amino acids that function as cellular signaling molecules—your body produces thousands naturally as part of normal physiology. The recent regulatory shift involves the restoration of legal compounding access for approximately 14 peptides that were restricted in late 2023, allowing licensed pharmacies to prepare them under physician supervision rather than forcing patients toward unregulated vendors.
The peptide landscape splits broadly into several functional categories: growth hormone secretagogues (CJC-1295, Ipamorelin) that stimulate your own GH release; tissue repair compounds (BPC-157, TB-500) studied primarily in animals for tendon and ligament healing; neurological peptides (Selank, Semax) investigated in early research for mood and cognition; cellular repair agents (GHK-Cu, Epitalon) associated with longevity research; and the GLP-1 class (semaglutide, tirzepatide) now widely prescribed. Most peptides outside the GLP-1 category lack the large randomized controlled trials required for standard FDA approval, though many have animal data or small pilot studies.
Why it matters for you
If you've been sourcing peptides through gray-market "research only" vendors, the regulatory change creates a clearer path to pharmaceutical-grade compounds. Independent testing of unregulated products has found significant quality problems—mislabeled contents, absent active ingredients, and bacterial contamination. Accessing peptides through a licensed pharmacy with a physician's prescription removes these sourcing risks.
For MyKine users tracking recovery, the tissue-repair peptides generate the most interest, but evidence remains preliminary. Studies exist mostly in animal models or small human pilots; you won't find the large trials that typically establish efficacy in humans. Similarly, if you're considering peptides for body composition, cognition, or longevity, the gap between what animal work suggests and what's proven in people is substantial. The regulatory shift doesn't change the evidence base—it just means you can now pursue it through proper medical channels rather than accepting contamination risk.
The practical takeaway: work with a physician familiar with peptides and a licensed compounding pharmacy. Document your baseline biomarkers and clinical goals clearly before starting. The compounds themselves may be useful, but quality assurance and medical oversight are where the real safety and efficacy gains live.
Caveats
- Most peptides outside GLP-1 compounds lack large randomized controlled human trials; evidence is primarily preclinical or observational
- Tissue-repair peptides (BPC-157, TB-500) have been studied mainly in animals, not extensively in humans
- Cognitive and mood peptides (Selank, Semax) were studied primarily in Russian research contexts; limited independent replication
- Gray-market testing data shows significant quality failures, but this reflects sourcing problems, not necessarily the peptides' pharmacology
- Regulatory approval status changed in February 2026; enforcement and implementation timelines remain uncertain